Intrinsiqq
Nanoviricides Inc. logo

Nanoviricides Inc. Financials

NNVC

Compare

All currency values in $ millions unless otherwise noted

Scroll

Showing 6 of 17 available years
Income Statement
TTM
JUN 2026
~1.3:1 split
JUN 2025
JUN 2024
JUN 2023
JUN 2022
Revenues
Revenue$0$0$0$0$0–
General & Administrative$4$4$4$3$3$2
Research & Development$8$5$6$5$6$6
Total Operating Expenses$12$8$10$9$9$8
Operating Income-$12-$8-$10-$9-$9-$8
Non-Operating
Net Interest Expense––-$0-$0-$0-$0
Other Non-Operating Income (Expense)$0$0$0$0$0$0
EBT (Earnings Before Tax)–-$8–––-$8
Income Tax Expense–$0––––
Net Income
Net Income-$12-$8-$9-$8-$9-$8
Per Share Data
Revenue Per Share$0.00$0.00$0.00$0.00$0.00–
EPS (Basic)-$0.54-$0.41-$0.63-$0.70-$0.74-$0.70
EPS (Diluted)-$0.54-$0.41-$0.63-$0.70-$0.74-$0.70
Weighted Avg Shares (Basic)24.8M20.2M15.1M11.9M11.6M11.5M
Weighted Avg Shares (Diluted)24.8M20.2M15.1M11.9M11.6M11.5M
Shares Outstanding24.8M20.2M15.1M11.9M11.6M11.5M

Nanoviricides (NNVC) financials: revenue, profit and margins

Nanoviricides (NNVC) generated about $0.00 in revenue and -$12 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

What is Nanoviricides's (NNVC) revenue?+

Nanoviricides generated about $0.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.

Is Nanoviricides profitable?+

Nanoviricides reported about -$12 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 14 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 17 Nov 2026. How this is calculated.

Fiscal year ends Jun.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NNVC

CompareIntrinsic value
JUNSJupiter Neurosciences Inc.
$1.24-15.41%10
MTNBMatinas Biopharma Holdings Inc.
$0.80-1.23%40
TRAWTraws Pharma Inc.
$0.18-23.91%40
LIXTLixte Biotechnology Holdings Inc.
$2.26-20.88%0
CNTBConnect Biopharma Holdings Ltd.
$0.59-6.05%10
ATNMActinium Pharmaceuticals Inc.
$1.05-1.87%30
GNLXGenelux Corp.
$2.17-4.82%10
NRXPNRx Pharmaceuticals, Inc.
$2.15-15.69%14

Spot a number that looks wrong? Check it in NNVC's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing NNVC

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.